Rolling Out7d
A breakthrough in Parkinson’s disease detection
AI-powered blood test detects Parkinson's disease years before symptoms appear, revolutionizing early diagnosis and treatment ...
MedPage Today14h
Why Did a GLP-1 Receptor Agonist Fail This Parkinson's Trial?
The GLP-1 receptor agonist exenatide failed to meet its primary outcome in a phase III trial of Parkinson's disease patients.
Medscape4h
Despite Early Promise GLP-1 Disappoints in Parkinson’s Disease
Exenatide had no disease-modifying effects in a phase 3 trial Parkinson’s disease, despite earlier evidence from a phase 2 ...
Sun Sentinel25d
Parkinson’s tremors disappear with use of machine that sends heat waves to the brain
This advanced platform utilizes focused ultrasound guided by MRI to precisely target and ... disorders such as essential tremor and Parkinson’s disease. (Mike Stocker/South Florida Sun Sentinel ...
New OHSU study examines potential link between PTSD, sleep issues and Parkinson's disease
Veterans diagnosed with post-traumatic stress disorder may experience thrashing sleep, which can lead to more extensive ...
GLP-1 drug shows little benefit for people with Parkinson's disease, trial finds
The GLP-1 drug, exenatide, has no positive impact on the movement, symptoms or brain imaging of people with Parkinson's, ...
Healio1d
GLP-1 does not slow Parkinson’s disease progression in phase 3 study
Treatment with exenatide, a GLP-1 receptor agonist, was comparable to placebo in slowing the rate of Parkinson’s disease ...